YN340169 WP1066 857064-38-1

WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. Phase 1.

YN340102 SC99 882290-02-0

SC99 is an orally active, selectiveSTAT3inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kin...

YN340209 AMG-47a 882663-88-9

AMG-47a is a potent, nonselective inhibitor of Lck kinase with IC50 of 3.4 uM and it also inhibits T cell proliferation. AMG-47a exhibit anti-inflammatory activity (ED50) of 11 mg/kg in the anti-CD3-induced production ...

YN340127 BD750 892686-59-8

BD750 is an immunosuppressant and a dual inhibitor of JAK3 and STAT5 that inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation with IC50 of 1.5 μM and 1.1 μM for mouse and human T-cell prol...

YN340235 AT9283 896466-04-9

AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM in cell-free assays also potent to Aurora A/B, Abl(T315I). Phase 2.

YN340057 AZ960 905586-69-8

AZ960 is a potent and specific inhibitor of theJAK2kinase with a Ki of 0.45nM.

YN340029 AZD-1480 935666-88-9

AZD-1480 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50s of 1.3nM and <0.4 nM, respectively.

YN340056 TG101209 936091-14-4

TG101209 is a selectiveJAK2inhibitor with IC50 of 6nM, less potent toFlt3 and RETwith IC50 of 25nM and 17nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutatio...

YN340054 Fedratinib 936091-26-8

Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally activeJAK2inhibitor with IC50s of 3nM for bothJAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JA...

YN340166 SB1317 937270-47-8

SB1317 is a potent inhibitor of CDK2,JAK2, and FLT3for the treatment of cancer, with IC50 of 13, 73, and 56nM for CDK2, JAK2 and FLT3, respectively.

YN340191 Pacritinib 937272-79-2

Pacritinib is a potent inhibitor of both wild-typeJAK2(IC50=23nM)  and JAK2V617Fmutant (IC50=19nM). Pacritinib also inhibitsFLT3(IC50=22nM)  and  its mutantFLT3D835Y(IC50=6nM).

YN340085 G5-7 939681-36-4

G5-7, an orally activeJAK2inhibitor, selectively inhibits JAK2–mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 has the potential for glioma study.

YN340236 Ruxolitinib 941678-49-5

Ruxolitinib (INCB18424) is a potent and selectiveJAK1/2inhibitor with IC50s of 3.3nM and 2.8nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib inducesautophagy and kills tumor ce...

YN340237 Ruxolitinib (S enantiomer) 941685-37-6

Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib S enantiomer is aJAKinhibitor

YN340218 Peficitinib 944118-01-8

Peficitinib is an oralJAKinhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

YN340101 Decernotinib 944842-54-0

Decernotinib is a potent, orally activeJAK3inhibitor, with Kis of 2.5, 11, 13 and 11nM forJAK3, JAK1, JAK2, and TYK2, respectively.

YN340147 XL019 945755-56-6

XL019 is a potent，orally active, and selectiveJAK2inhibitor, with IC50s of 2.2, 134.3, and 214.2nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of o...

YN340104 ZM39923 hydrochloride 1021868-92-7

ZM 39923 HCl is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR also found to be sensitive to transglutaminase.

YN340067 Momelotinib 1056634-68-4

Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Phase 3.

YN340068 Momelotinib sulfate 1056636-06-6

Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor ofJAK1/JAK2with IC50 of 11nM/18nM, 10-fold selectivity versus JAK3 (IC50=155nM).